Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

Shares of Vertex Pharmaceuticals (NASDAQ ... that Vertex is marketing and developing in partnership with CRISPR Therapeutics (NASDAQ: CRSP). As a treatment administered only once, it carries ...

The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth Stock Is a No-Brainer Buy on ...

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...

Vertex Pharmaceuticals (NASDAQ ... Vertex's collaboration with CRISPR Therapeutics on gene editing approaches for sickle cell disease treatment further strengthens its position in this field.

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology ... Vertex's collaboration with CRISPR Therapeutics on gene editing approaches for sickle cell disease treatment further strengthens its ...